Roivant Sciences Ltd. (ROIV) stock

ROIVNasdaqPharmaceutical PreparationsFiscal year ends March 31

Financials through Q2 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 9, 2026Score 8/30

$39.53−0.46 (-1.15%)

Close on Nov 13, 2026Market cap $28.55BP/E –Yield –

Roivant Sciences gross margin

Gross margin is gross profit as a percentage of revenue.

Change is against the same quarter a year earlier.

Periods

Period	Period end	Value	Change (pts)
Q2 FY2026CQ3 2026	Sep 30, 2026	90.5%	–
Q2 FY2025CQ3 2025	Sep 30, 2025	92.9%	–

Parsed from the XBRL in Roivant Sciences's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is ROIV.

Revenue growth102.1% · median -44.6%

Operating margin-1358.1% · median -540.7%

Net margin-838.2% · median -471.3%

Advertisement
300 × 250

See a number that looks wrong?